Clinical and Biochemical Effects of Hyaluronic Acid (Gel and Mouthrinse) on Periodontitis
Periodontitis
Enrolment: 24 · Results not recorded
Loading the evidence…
Device · Crosslinked high-molecular-weight hyaluronan (hylan G-F 20, marketed as Synvisc) used as a viscosupplement/viscoelastic matrix; ChEMBL max_phase 3, no mechanism-of-action record. ChEMBL also holds the generic parent entity CHEMBL5314376 HYALURONIC ACID (max_phase 4, ATC S01KA51) and CHEMBL4594244 HYALURONATE SODIUM (max_phase 4, ATC M09AX01/S01KA01/D03AX05/R01AX09); get_mechanism for CHEMBL5314376 returned zero mechanisms, consistent with a physical/viscoelastic rather than receptor-mediated mode of action.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Periodontitis
Enrolment: 24 · Results not recorded
Dermal Filler · Volume Deficiency of the Midface
Enrolment: 72 · Results not recorded
Nasolabial Folds
Enrolment: 50 · Results not recorded
Gingival Destruction
Enrolment: 24 · Results not recorded
Medication Related Osteonecrosis of the Jaw
Enrolment: 10 · Results not recorded
Oral Mucositis Due to Radiation
Enrolment: 48 · Results not recorded
Aesthetic Body Volume Loss
Enrolment: 80 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Spinal dorsal hemisection injury
High molecular weight hyaluronic acid hydrogel implants reduced immune cell infiltration, CSPG deposition and astrocyte activation after spinal cord injury.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.